Dr George Sharbeen is co-lead of the Pancreatic Cancer Translational Research Group (UNSW Sydney) and a senior research fellow in the Poor Outcomes Cancers focus area, within the Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group. His research is focused on developing more effective therapies for pancreatic cancer and his most notable achievements include co-development of a novel nanomedicine for pancreatic cancer and a 3D human pancreatic cancer explant model, and the identification of an amino acid transporter as a stromal remodelling target in pancreatic cancer. His work formed the foundation for the SPEAR (Sulfasalazine in patients with PancrEatic AdenocaRcinoma) clinical trial (part of the Molecular Screening and Therapeutics [MoST] pancreas cancer program) where Dr Sharbeen co-leads the correlative science studies. His research success has been recognised by a number of awards and competitive research funding including Cancer-Institute NSW Early-Career and Mid-Career Fellowships. He is currently funded by Pankind Accelerator and NSW Health Advanced Therapeutics Impact grants.